Clinical trials
Advanced Tumors clinical trials
Below are recruiting advanced tumors clinical trials, each written for real people, not researchers. We’re tracking 1,356 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06402201RecruitingPhase 1
First human trial of CDR404 for MAGE-A4 positive solid tumors
This trial tests an experimental treatment called CDR404 for people with certain advanced solid tumors. It is designed for those whose tumors have a specific protein (MAGE-A4) and who have already tried other treatments. The goal is to see if the treatment is safe and effective.
Miami, FloridaAges 18 years+ - NCT07290088RecruitingPhase 2/Phase 3
Testing a new drug for advanced solid tumors
This trial tests a new drug called PRL3-zumab for people with advanced solid tumors (cancers that have spread). The goal is to see if it can shrink tumors or slow their growth. It is an option for patients who have had limited prior treatments.
Kota BharuAges 18–75 - NCT07050459RecruitingPhase 1
Study of SIM0686 for advanced solid tumors
This trial tests a new drug (SIM0686) in people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and how it affects tumors that have a specific protein called FGFR2b on their surface.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05732831RecruitingPhase 1/Phase 2
Study drug for tumors with MTAP loss
This Phase 1/2 trial tests TNG462 (with or without pembrolizumab, depending on the plan) in solid tumors that have lost MTAP. The goal is to check safety and learn whether the treatment can help people with these specific tumor changes.
Palo Alto, CaliforniaAges 18 years+ - NCT06390774RecruitingPhase 1
Study of SSGJ-705 for advanced cancers
This phase 1 trial tests a new targeted drug (SSGJ-705) for people with advanced solid tumors or lymphomas. Doctors will check safety and find the best dose, and there may be a chance the drug helps shrink or control the cancer.
Jinan, ShandongAges 18–75 - NCT07250386RecruitingPhase 1
CEA-targeted CAR-T therapy for advanced solid tumors
This trial tests a new CAR-T cell therapy that targets CEA, a protein found on certain cancer cells. It's for people with advanced solid tumors like lung or breast cancer who have not responded to other treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT06915753RecruitingPhase 1
TYRA-430 for advanced liver cancer and other solid tumors
This trial tests an oral drug called TYRA-430 for people with advanced liver cancer (HCC) or other solid tumors that have changes in the FGF/FGFR pathway. It aims to see how safe the drug is and whether it can shrink tumors or slow cancer growth.
Los Angeles, CaliforniaAges 18 years+ - NCT05477849RecruitingPhase 1
Study drug for people with advanced solid tumors
This Phase 1 trial tests the safety and early effects of VG2025 in people with advanced solid cancers that have stopped responding to standard treatments. It’s mainly looking for side effects and how the body processes the drug, and it may offer a new option when other treatments haven’t worked.
Hangzhou, ZhejiangAges 18–75 - NCT07448922RecruitingPhase 2
Study of SKB518 for advanced gynecologic cancers
This trial tests a new drug called SKB518, either alone or with other treatments, for people with advanced gynecologic cancers (ovarian, cervical, or endometrial) who have already had some treatment. It aims to see if the drug helps shrink or control the cancer.
ChongqingAges 18–75 - NCT07262164RecruitingPhase 1
Testing VG2062 for advanced solid tumors
This trial is testing a new drug called VG2062 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how the body processes it.
HebeiAges 18–75 - NCT07002203RecruitingPhase 1/Phase 2
Personalized cancer vaccine trial for solid tumors
This trial tests a custom-made vaccine designed to train your immune system to fight your specific cancer. It may be an option if you have advanced cancer that stopped responding to treatment or early-stage cancer with a high risk of coming back.
BangkokAges 20 years+ - NCT05208047RecruitingPhase 3
CGT9486 plus sunitinib for advanced gastrointestinal stromal tumors
This trial tests whether adding a new drug called CGT9486 to sunitinib (a standard cancer drug) works better than sunitinib alone for gastrointestinal stromal tumors (GISTs) that have grown or spread. You may qualify if your GIST stopped responding to or caused problems with imatinib, an earlier treatment.
Birmingham, AlabamaAges 18 years+ - NCT05270213RecruitingPhase 1
RBS2418 for advanced cancers after standard treatments
This early-phase study tests RBS2418 in people with advanced, metastatic solid tumors that have not responded to standard treatment. It aims to see if the drug can shrink tumors or help control disease, and to learn what doses are safest.
Scottsdale, ArizonaAges 18 years+ - NCT06063681RecruitingPhase 1
Testing a new ENPPI inhibitor for advanced solid tumors
This trial tests a new drug, SR-8541A, that blocks an enzyme called ENPPI, which may help slow or stop tumor growth. It is for people with advanced or metastatic solid tumors who have not responded to other treatments or have no standard options.
Randwick, New South WalesAges 18 years+ - NCT06190886RecruitingPhase 1
First-in-human study of PTX-912 for advanced solid tumors
This trial tests a new drug called PTX-912 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It is a first-in-human study, meaning this is the first time PTX-912 is being given to people, to see how safe it is and how well it works.
Duarte, CaliforniaAges 18 years+ - NCT06726564RecruitingPhase 1
Study of MT027 for malignant pleural effusion
This trial tests a new drug called MT027 for people with advanced cancer that has spread to the lining around the lungs (pleura) and caused fluid buildup. The drug targets a marker on cancer cells called B7-H3. It may help control the fluid and the cancer.
BeijingAges 18 years+ - NCT07455617RecruitingPhase 1
Vaccine for KRAS-mutated advanced solid tumors
This trial tests a new vaccine, ABO2102, for people with advanced solid tumors that have a specific change in the KRAS gene. The vaccine aims to help your immune system fight the cancer.
ShanghaiAges 18 years+ - NCT07224464Recruiting
Sarah Nanotechnology System for advanced solid tumors using heat therapy
This trial tests a new nanotechnology system that uses controlled heat to treat advanced solid tumors in the chest or abdomen that have not responded to standard treatments. It may be an option if you have few remaining choices and want to explore a novel approach.
Rochester, MinnesotaAges 18 years+ - NCT07363967RecruitingPhase 1
Study of SWA1211 for advanced solid tumors
This trial tests a new oral drug, SWA1211, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and works against the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05831033RecruitingEarly Phase 1
Your own immune T-cells to treat advanced solid tumors
This early-phase study tests a treatment made from your own tumor-fighting immune cells (TIL cells) for advanced solid cancers that have worsened or no longer respond to standard therapy. The main goal is to learn whether it is safe and whether it can shrink tumors for people who have limited options.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT03658785RecruitingPhase 1/Phase 2
Immunotherapy for advanced solid tumors using patient tumor cells
This trial tests an immunotherapy made from your own tumor-fighting immune cells (TIL). It may help people with advanced solid cancers that cannot be cured with surgery or radiation.
Wuhan, HubeiAges 18–70 - NCT04952272RecruitingPhase 1
Shots into the tumor to boost the immune system
This Phase 1 study tests an injection given directly into an advanced solid tumor to help the immune system better recognize and attack cancer. It may help people with advanced solid tumors, but the goal at this early stage is mainly to check safety and how the treatment works.
Guangzhou, GuangdongAges 18–80 - NCT07213817RecruitingPhase 1/Phase 2
Safety and effectiveness of IPN60300 for advanced solid tumors
This trial tests a new drug called IPN60300 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink tumors.
New Haven, ConnecticutAges 18 years+ - NCT07390838RecruitingPhase 1
Study of SH009 for advanced solid tumors
This trial tests an investigational drug called SH009 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
ShanghaiAges 18 years+
Hear when a new Advanced Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced tumors?
- Yes. Clin2 currently lists 1,356 recruiting advanced tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Advanced or Metastatic Solid Tumors
- Locally Advanced or Metastatic Solid Tumors
- Advanced Malignant Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Patients With Advanced Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Mesothelin-positive Advanced Malignant Solid Tumors
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.